Janux Therapeutics, Inc. - Common Stock (NQ:JANX)

14.21 +0.03 (+0.18%)

Streaming Delayed Price Updated: 3:48 PM EDT, May 11, 2026 Add to My Watchlist

Price and Volume

Volume	525,093
Open	14.34
Bid (Size)	14.20 (600)
Ask (Size)	14.21 (200)
Prev. Close	14.18
Today's Range	14.06 - 14.70
52wk Range	12.12 - 35.34
Shares Outstanding	41,833,315
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Janux Therapeutics Reports First Quarter 2026 Financial Results and Business Highlights

May 07, 2026

From Janux Therapeutics

Via Business Wire

Janux Therapeutics Announces Discontinuation of JANX008 Clinical Development

April 27, 2026

From Janux Therapeutics, Inc.

Via Business Wire

Performance

YTD	+4.1%	+4.1%
1 Month	-4.9%	-4.9%
3 Month	+7.0%	+7.0%
6 Month	-48.5%	-48.5%
1 Year	-45.5%	-45.5%

More News

Janux Therapeutics Announces First Participant Dosed in Phase 1 Study of JANX014

April 16, 2026

From Janux Therapeutics

Via Business Wire

Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration, Triggering $35 Million Milestone Payment

April 01, 2026

From Janux Therapeutics

Via Business Wire

Janux Stock Is Rising Pre-Market After A New Oncology Deal With Bristol Myers Squibb ↗

January 22, 2026

Via Stocktwits

Janux Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

February 26, 2026

From Janux Therapeutics

Via Business Wire

Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011

February 17, 2026

From Janux Therapeutics

Via Business Wire

Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer

January 26, 2026

From Janux Therapeutics

Via Business Wire

Janux Therapeutics Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop a Novel Tumor-Activated Therapeutic for Solid Tumors

January 22, 2026

From Janux Therapeutics

Via Business Wire

Janux Therapeutics Provides Program Update on Ongoing Phase 1 JANX008 Study

December 23, 2025

From Janux Therapeutics

Via Business Wire

Options Exercise: Janux Executive Sells 16,665 Shares for $501,000 ↗

December 04, 2025

Via The Motley Fool

Which stocks are moving on Tuesday? ↗

December 02, 2025

Via Chartmill

Top movers analysis in the middle of the day on 2025-12-02: top gainers and losers in today's session. ↗

December 02, 2025

Via Chartmill

Janux Therapeutics Stock Sinks 50% After Prostate Cancer Trial Triggers Target Cuts Across Wall Street — Retail Sees A FOMO-Fueled Rebound ↗

December 02, 2025

Via Stocktwits

Which stocks are gapping on Tuesday? ↗

December 02, 2025

Via Chartmill

Janux Therapeutics Craters 50% On Prostate Cancer Update; Is It An 'Overreaction'? ↗

December 02, 2025

Via Investor's Business Daily

These stocks are moving in today's pre-market session ↗

December 02, 2025

Via Chartmill

What's going on in today's after hours session ↗

December 01, 2025

Via Chartmill

Janux Announces Encouraging Efficacy and Safety Profile from Ongoing Phase 1 Clinical Trial for JANX007 in mCRPC

December 01, 2025

From Janux Therapeutics

Via Business Wire

Janux Therapeutics to Host Virtual Event Discussing Updated Phase 1a and Phase 1b Clinical Data for JANX007 in mCRPC

November 24, 2025

From Janux Therapeutics

Via Business Wire

Janux Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights

November 06, 2025

From Janux Therapeutics

Via Business Wire

Janux (JANX) R&D Soars Revenue Misses ↗

August 07, 2025

Via The Motley Fool

Janux Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights

August 07, 2025

From Janux Therapeutics

Via Business Wire

Janux Therapeutics Announces Clinical Milestone Achievement in TRACTr Collaboration With Merck

August 05, 2025

From Janux Therapeutics

Via Business Wire

Janux Therapeutics Highlights Pipeline Progress and Best-in-Class Potential of Novel Bispecific Platform for Autoimmune Diseases at Virtual R&D Day

July 24, 2025

From Janux Therapeutics

Via Business Wire

Frequently Asked Questions

Is Janux Therapeutics, Inc. - Common Stock publicly traded?

Yes, Janux Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Janux Therapeutics, Inc. - Common Stock trade on?

Janux Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Janux Therapeutics, Inc. - Common Stock?

The ticker symbol for Janux Therapeutics, Inc. - Common Stock is JANX on the Nasdaq Stock Market

What is the current price of Janux Therapeutics, Inc. - Common Stock?

The current price of Janux Therapeutics, Inc. - Common Stock is 14.21

When was Janux Therapeutics, Inc. - Common Stock last traded?

The last trade of Janux Therapeutics, Inc. - Common Stock was at 05/11/26 03:48 PM ET

What is the market capitalization of Janux Therapeutics, Inc. - Common Stock?

The market capitalization of Janux Therapeutics, Inc. - Common Stock is 594.24M

How many shares of Janux Therapeutics, Inc. - Common Stock are outstanding?

Janux Therapeutics, Inc. - Common Stock has 594M shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.